Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q2

4521.TEDINET S100S89K
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥36.2bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥73.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥36.8bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥5.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥8.2bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥5.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥8.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥5.7bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥8.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.4bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥171.7bnat 2023-09-30Cons.Assets
Total assets¥166.3bnat 2023-03-31Cons.Assets
Total assets¥167.3bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥30.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥29.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥140.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥136.8bnat 2023-03-31Cons.Net assets
Net assets / equity¥140.4bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥55.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥59.6bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥70.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.3bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥75.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥245m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥9.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥7.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥4.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥108.182023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥41.292023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.82022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥158.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥81.452022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio82.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio81.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2023-04-01 → 2023-09-30¥661m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥7.6bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-09-30¥616m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥8.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration36819000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember7592000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember616000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember8209000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration8209000000JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember34192000000JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember－JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember34192000000JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_ReconcilingItemsMember－JPY
Net sales of finished goods and merchandiseCurrentYTDDuration34192000000JPY
RoyaltyCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember765000000JPY
RoyaltyCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember－JPY
RoyaltyCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember765000000JPY
RoyaltyCurrentYTDDuration_ReconcilingItemsMember－JPY
RoyaltyCurrentYTDDuration765000000JPY
Other incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember－JPY
Other incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember1212000000JPY
Other incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1212000000JPY
Other incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Other incomeCurrentYTDDuration1212000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember34958000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember1212000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember36171000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration36171000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember34958000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember1212000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember36171000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration36171000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember4851000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember661000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember5512000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating incomeCurrentYTDDuration5512000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第104期第２四半期(自　2023年７月１日　至　2023年９月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)科研製薬株式会社
Company name in english cover pageFilingDateInstantKAKEN PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　堀　内　裕　之

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass